Drug Trial Radar · NCT04620330
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Dec 31, 2020
Primary completion
Aug 29, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
Conditions
- Non Small Cell Lung Cancer
- KRAS Activating Mutation
Interventions
avutometinib (VS-6766)Drug
Monotherapy
avutometinib (VS-6766) and DefactinibDrug
Combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the optimal regimen, either avutometinib (VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, in KRAS-G12V NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
- To evaluate the initial efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
- To determine efficacy in KRAS-other (non-G12V) NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
- To determine the efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
Locations
45 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Colorado Hospital
Aurora, Colorado
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Emory University School of Medicine
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago Medical Center-Duchossois Center for Advanced Medicine
Chicago, Illinois
Illinois Cancer Specialists
Niles, Illinois
Hematology/Oncology Clinic, LLP
Baton Rouge, Louisiana
Maryland Oncology Hematology P.A
Columbia, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Northwell Health-Monter Cancer Center
Lake Success, New York
Zangmeister Cancer Center
Columbus, Ohio
Northwest Cancer Specialists, P.C.
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Univ. of Pittsburgh Med Center
Pittsburgh, Pennsylvania
Chattanooga Oncology Hematology Assoc.
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
Texas Oncology
Dallas, Texas
Texas Oncology Ft Worth Cancer Center
Fort Worth, Texas
Texas Oncology
Grapevine, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Centre Leon Berard
Lyon, France
Hopital Nord Marseille
Marseille, France
Hopital Cochin
Paris, France
Institute De Cancerologie De L'Ouest Site Paul Papin Oncologie Medicale
Saint-Herblain, France
Cancerologie Gustave Roussy - Cancer Medicine
Villejuif, France
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Universitatsklinkum Leipzig
Leipzig, Germany
Evangelisches Klinkum Bethel
Straße, Germany
Irccs, Irts
Meldola, Italy
UOC di Oncologia Medica
Parma, Italy
Centro Ricerche Cliniche di Verona
Verona, Italy
Azienda Ospedaliera Universitaria
Orbassano, Torino, Italy
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.